Publications by authors named "Fred Yang"

Claim this Profile
P
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment.
James McCabe, Jay Zhang, Fred Yang, Vincent Benn

Eur J Drug Metab Pharmacokinet· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study.
George L Bakris, Y Fred Yang, James M McCabe, Jin Rong Liu, Xiaojuan J Tan

Am J Hypertens· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
Ping Wang, Jinrong Liu, Xiaojuan Tan, Fred Yang, James McCabe

Eur J Drug Metab Pharmacokinet· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.
George Bakris, Pablo E Pergola, Belkis Delgado, Diyan Genov, Tamar Doliashvili, Y Fred Yang

Hypertension· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury.
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Y Fred Yang

Front Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19.
Tzu-Yi Chuang, Ming-Han Tsai, Lit-Min Wu, Sung-Jung Ho, Pu-Sheng Yeh, Hung-Jen Fred Yang

J Microbiol Immunol Infect· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
George Bakris, Y Fred Yang, Bertram Pitt

Hypertension· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models.
Xiaojuan Tan, Min Zhang, Qingmei Liu, Ping Wang, Tian Zhou, Fred Yang

Antimicrob Agents Chemother· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beware of on-treatment safety analyses.
Fred Yang, Janet Wittes, Bertram Pitt

Clin Trials· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Michael A Nauck, Murray W Stewart, Christopher Perkins, Angela Jones-Leone, Fred Yang

Diabetologia· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements.
Fred Yang, Murray Stewart, June Ye, David DeMets

Diabetes Metab Syndr Obes· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Lawrence A Leiter, Molly C Carr, Murray Stewart, Angela Jones-Leone, Rhona Scott, Fred Yang

Diabetes Care· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Julio Rosenstock, Vivian A Fonseca, Jorge L Gross, Robert E Ratner, Bo Ahrén, Fred Yang

Diabetes Care· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Bo Ahrén, Susan L Johnson, Murray Stewart, Deborah T Cirkel, Fred Yang

Diabetes Care· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.
Malcolm A Young, Jeffrey A Wald, Jessica E Matthews, Fred Yang, Rickey R Reinhardt

Postgrad Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials.
Fred Yang, June Ye, Kenneth Pomerantz, Murray Stewart

Diabetes Metab Syndr Obes· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
Yutaka Seino, Hiromu Nakajima, Hajime Miyahara, Takashi Kurita, Mark A Bush, Fred Yang

Curr Med Res Opin· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
Julio Rosenstock, Jane Reusch, Mark Bush, Fred Yang, Murray Stewart

Diabetes Care· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis